Männedorf
Männedorf
Männedorf, Switzerland3 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder, skin disorder | Active, not recruiting | Phase 3 | 2025-12-30 | NCT02051218 | |
| Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung cancer, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Active, not recruiting | Phase 2 | 2025-10-01 | NCT04472949 | |
| Thyroidectomy for Graves' Disease or Amiodarone-induced Thyrotoxicosis | Graves disease, autoimmune disease, disease of orbital part of eye adnexa, endocrine system disorder, exophthalmos, eye disorder, goiter, hyperthyroidism, immune system disorder, thyroid crisis, thyroid gland disorder, thyrotoxicosis | Recruiting | Not stated | 2025-07-02 | NCT06963203 |